These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1516763)

  • 1. Metabolism of HDL apolipoprotein A-I and A-II in type 1 (insulin-dependent) diabetes mellitus.
    Taskinen MR; Kahri J; Koivisto V; Shepherd J; Packard CJ
    Diabetologia; 1992 Apr; 35(4):347-56. PubMed ID: 1516763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus.
    Frénais R; Nazih H; Ouguerram K; Maugeais C; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M
    J Clin Endocrinol Metab; 2001 May; 86(5):1962-7. PubMed ID: 11344192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution.
    Brinton EA; Eisenberg S; Breslow JL
    Arterioscler Thromb; 1994 May; 14(5):707-20. PubMed ID: 8172849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM.
    Kahri J; Groop PH; Viberti G; Elliott T; Taskinen MR
    Diabetes; 1993 Sep; 42(9):1281-8. PubMed ID: 8349039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
    Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
    Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus.
    Schernthaner G; Kostner GM; Dieplinger H; Prager R; Mühlhauser I
    Atherosclerosis; 1983 Dec; 49(3):277-93. PubMed ID: 6229255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein A-II, HDL metabolism and atherosclerosis.
    Tailleux A; Duriez P; Fruchart JC; Clavey V
    Atherosclerosis; 2002 Sep; 164(1):1-13. PubMed ID: 12119188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia.
    Saku K; Gartside PS; Hynd BA; Mendoza SG; Kashyap ML
    Metabolism; 1985 Aug; 34(8):754-64. PubMed ID: 3927110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency.
    Tilly-Kiesi M; Packard CJ; Kahri J; Ehnholm C; Shepherd J; Taskinen MR
    Atherosclerosis; 1997 Feb; 128(2):213-22. PubMed ID: 9050778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity.
    Ruotolo G; Parlavecchia M; Taskinen MR; Galimberti G; Zoppo A; Le NA; Ragogna F; Micossi P; Pozza G
    Diabetes Care; 1994 Jan; 17(1):6-12. PubMed ID: 8112191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
    Pietzsch J; Julius U; Nitzsche S; Hanefeld M
    Diabetes; 1998 Dec; 47(12):1928-34. PubMed ID: 9836526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII).
    Tilly-Kiesi M; Lichtenstein AH; Ordovas JM; Dolnikowski G; Malmström R; Taskinen MR; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):873-80. PubMed ID: 9157950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
    Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
    Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.
    Duvillard L; Florentin E; Lalanne-Mistrich ML; Petit JM; Baillot-Rudoni S; Brun-Pacaud A; Brun JM; Gambert P; Vergès B
    Diabetologia; 2005 Jul; 48(7):1366-72. PubMed ID: 15918022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product.
    Alaupovic P; Wang CS; McConathy WJ; Weiser D; Downs D
    Arch Biochem Biophys; 1986 Jan; 244(1):226-37. PubMed ID: 3080947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men.
    Bagdade JD; Subbaiah PV
    Diabetes; 1989 Oct; 38(10):1226-30. PubMed ID: 2507376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic animals with altered high-density lipoprotein composition and functions.
    Kalopissis AD; Chambaz J
    Curr Opin Lipidol; 2000 Apr; 11(2):149-53. PubMed ID: 10787176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.